Clover Health stock rose 12.7% to about US$4.67 into the close, and the mood shift is all about profitability finally showing up in the numbers. The company reported Q2 net income of US$28 million on revenue of US$743 million, its second straight profitable quarter, which is notable for a Medicare Advantage insurer that has spent years in the red.

The market appears focused on that earnings shift and the raised 2026 guidance for revenue and adjusted EBITDA. The key question for investors now is whether this profitability run rate looks durable or is being treated as a victory lap too soon.

Is Clover Health Investments now a genuine undervalued turnaround story, or is the low P/S and big gap to that DCF estimate sending a false signal? See how the stock screens on our valuation analysis for Clover Health Investments

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$743.2 million vs. US$477.6 million (very large increase, roughly 1.6x)
• Net Income, Q2 2026 vs. Q2 2025: US$28.0 million profit vs. US$10.6 million loss (moved from loss to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.053 vs. a loss of US$0.021 per share (moved from loss to positive EPS)
• Adjusted EBITDA, Q2 2026 vs. Q2 2025: US$41 million vs. a loss in the prior year period (shifted to positive adjusted EBITDA, a commonly used non GAAP profitability metric)

Prefer clean, visual charts instead of another wall of numbers and earnings tables? See Clover Health Investments' full financial picture with a focus on its valuation in our company report for Clover Health Investments.

Clover Health’s Profit Story Meets Real Operating Milestones

The bullish story on Clover Health is that AI driven care at the point of service can turn a small Medicare Advantage insurer into a consistently profitable platform. Q2 results move that from theory toward evidence. Average MA membership rose about 48% to roughly 157,000 and revenue reached US$743.2 million, yet the company still produced US$28 million of net income and US$41 million of adjusted EBITDA. That combination of scale and profitability is a key milestone for the thesis that cohort economics are improving rather than just being managed by one off cost actions.

Management’s focus on cohort maturation and AI enabled clinical decisions is also showing up in higher consolidated gross profit of US$153 million and positive operating cash flow of US$133 million in the first half. For a business that used to run at a loss, two straight profitable quarters with raised full year guidance directly support the turnaround narrative.

Reveal where the surface looks calm, yet the multi year models start to disagree on Clover Health Investments' trajectory, and see what the street is quietly baking in for revenue, earnings and cash flow inflection points with our analyst estimates for Clover Health Investments.

Clover Health Bears Still See Unfinished Business

The core bearish claim on Clover Health is that healthcare cost inflation, regulatory uncertainty and scale risk will eventually overwhelm early profitability. The latest quarter clearly pushes back on the idea that the model cannot reach the black, with US$28 million of net income, US$41 million of adjusted EBITDA and US$133 million of operating cash flow in the first half. However, several milestones that matter to the bears remain unresolved.

Regulatory and legal overhangs are intact. The Department of Justice and SEC inquiries into potential securities fraud are still live, and CMS has signaled an appeal of the 4.5 Star rating recalculation that underpins Payment Year 2027 economics. Execution risk on cohort maturation also remains. Management itself flags elevated outpatient trends versus prior years and expects seasonal pressure in Q4, which means the durability of medical cost control is not yet proven over a full claims cycle.

After CMS pushback, regulatory probes and seasonal cost pressure, are these issues contained or early red flags? Review our risk analysis for Clover Health Investments which shows 1 important warning sign

Stay Ahead With Simply Wall St

If Clover Health Investments looks interesting after two straight profitable quarters and raised guidance, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the thesis evolves. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the key fundamental updates that matter to your holdings. For a longer term view, tap into crowd wisdom and sentiment through the Community and see how other investors are interpreting new data points. By spotting potential catalysts and risks early, you can stay ahead of the market and make more confident decisions.

Seeking Alternatives Beyond Clover Health?

Clover Health Investments may be on your radar, but fresh ideas move fast. Spot breakout momentum and under the radar opportunities before the crowd reacts.

• Target resilient payoffs in a choppy market and review the curated 77 resilient stocks with low risk scores that focus on capital preservation while it still flies under the radar for now.
• Review developments in structural energy shifts and scan the hand picked 89 nuclear energy infrastructure stocks before momentum traders react to these infrastructure plays.
• Position ahead of possible metals catalysts and sift through the carefully filtered 28 best rare earth metal stocks while pricing dislocations remain fresh and entry points have not yet been crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.